Back

Progressive disease substrate in obese type 2 diabetic patients with coronary artery disease despite achieving HbA1c <7.0%: sub-analysis from the OPTIMAL randomized study

1 September 2025 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart (3) Pathophysiology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Anthony Salib

Austin Hospital, Melbourne (Australia)

4 More presentations in this session

Presentation thumbnail
GLP-1 receptor agonists and SGLT2-inhibitors in patients with diabetes and ischaemic heart disease in primary care
Doctor T. Andersson (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study
Ms B. Sharad (Malmo, SE)
Abstract Slides Video
Presentation thumbnail
Tirzepatide and the risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials
Doctor E. Mansouri (Tehran, IR) Mr L. Barbosa (Belo Horizonte, BR)
Abstract Slides Video
Presentation thumbnail
The impact of age of onset and duration of Type 2 diabetes on life expectancy and serious health outcomes
Doctor J. Isufi (Gothenburg, SE)
Abstract Slides

Access the full session

Session thumbnail
Diabetes and the heart (3)

The Event

Event poster

ESC Congress 2025

1 September 2025 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Different response of plaque regression under achieving LDL-C <1.8 mmol/L in non-obese and obese diabetic patients with coronary artery disease: a sub-analysis from the OPTIMAL randomized study
thumbnail
Congress Presentation
Body mass index as a contributor to the accumulation of lipidic plaque materials in statin-treated type 2 diabetic patients with coronary artery disease: sub-analysis from the OPTIMAL randomized study
thumbnail
Congress Presentation
Apolipoprotein B and the regression of lipidic plaque in statin-treated type 2 DM patients with coronary artery disease: the pre-specified sub-analysis from the OPTIMAL randomized controlled trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources